<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624853</url>
  </required_header>
  <id_info>
    <org_study_id>YMC042</org_study_id>
    <nct_id>NCT05624853</nct_id>
  </id_info>
  <brief_title>A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain</brief_title>
  <official_title>A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare the efficacy and safety of pregabalin sustained release tablet and&#xD;
      pregabalin immediate release capsule in type II diabetic patients with peripheral neuropathic&#xD;
      pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 8 in Visual Analogue Scale(VAS)</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in Quality of Life(EQ-5D)</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in Patients Global Impression of Change(PGIC)</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in Clinician Global Impression of Change(CGIC)</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in Daily Sleep Interference Scale(DSIS)</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in Morisky Medication Adherence Scale 8-item version(MMAS-8)</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose and frequency of Rescue medication(Acetaminophen)</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of subjects with adverse event</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Neuropathic Pain</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>pregabalin sustained release tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pregabalin sustained release tablet 150mg qd for 8weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pregabalin immediate release capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pregabalin immediate release capsule 75mg bid for 8weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin sustained release tablet</intervention_name>
    <description>pregabalin sustained release tablet 150mg qd for 8weeks</description>
    <arm_group_label>pregabalin sustained release tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin immediate release capsule</intervention_name>
    <description>pregabalin immediate release capsule 75mg bid for 8weeks</description>
    <arm_group_label>pregabalin immediate release capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 19 years, &lt; 75 years&#xD;
&#xD;
          2. VAS score for diabetic peripheral neuropathy pain ≥ 30&#xD;
&#xD;
          3. Patients who have been administering pregabalin immediate release capsule 150 mg/day&#xD;
             for more than 4 weeks&#xD;
&#xD;
          4. Type II DM patient and HbA1c ≤ 10 %&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with hypersensitivity to pregabalin&#xD;
&#xD;
          2. Patient on anti-epileptic drugs&#xD;
&#xD;
          3. Patients with pain caused by other factors than diabetic peripheral neuropathy&#xD;
&#xD;
          4. Patients undergoing eGFR &lt;30 mL/min/1.73 m2 (MDRD) at screening&#xD;
&#xD;
          5. AST(Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) level ≥ 3x ULN (upper&#xD;
             limit of normal range) or active liver disease&#xD;
&#xD;
          6. Drug-abusing patient&#xD;
&#xD;
          7. Severe depression or uncontrolled abnormal mood and behavioral changes&#xD;
&#xD;
          8. Pregnant and breast-feeding woman&#xD;
&#xD;
          9. Patients who participated in other clinical trials for investigational products within&#xD;
             30 days of screening&#xD;
&#xD;
         10. Patients deemed to be ineligible to participate in the trial by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bon Jeong Ku</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <state>Chungcheongnam-do</state>
        <zip>31116</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Korea's Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>14647</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49267</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daejeon Eulji Medical Center, Eulji University</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Sejong Hospital</name>
      <address>
        <city>Sejong</city>
        <zip>30099</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pregabalin sustained release tablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

